 |
市場調查報告書
商品編碼
1516051
血清分離凝膠市場 - 副產品（不含整合管的血清分離凝膠、整合管的血清分離凝膠）、最終用途（醫院、血庫、製藥公司） - 全球預測（2024 - 2032）Serum Separation Gel Market - By Product (Serum Separation Gel Without Integrated Tubes, Serum Separation Gel with Integrated Tubes), End-use (Hospitals, Blood Banks, Pharmaceutical Companies)- Global Forecast (2024 - 2032) |
||||||
2024 年至 2032 年，全球血清分離凝膠市場的複合年成長率將達到 5.9%，這主要是由領先公司的產品擴張所推動的。這些擴展是為了滿足醫學實驗室對高效、可靠的診斷工具日益成長的需求。血清分離膠對血液分離的精密度和準確性起著重要作用，這對於診斷測試很重要。例如，2023 年 8 月，Osoh Corporation 宣布計劃在其位於山口縣周南的分離精煉廠推廣 TOYOPEARL-TSKgel PW 業務。這項決定是為了響應日益成長的淨化需求。
該公司正在大力投資先進製造設施和新技術，以提高效率並滿足不斷成長的全球需求。此外，慢性病盛行率的不斷上升以及定期健康檢查的需求進一步支撐了市場需求。因此，在領先的技術進步和戰略基礎設施的支持下，血清分離凝膠市場有望強勁成長。
血清分離凝膠產業的整體規模根據產品、最終用途和地區進行分類。
由於臨床研究環境中對簡單、經濟高效的解決方案的需求，整合無管血清分離凝膠細分市場將從 2024 年到 2032 年強勁成長。此外，診斷工作中對分析準確性和建模效率日益成長的需求也促進了這項需求。因此，製造商專注於在不使用整合設備的情況下提高血清分離凝膠的品質和可用性。
製藥公司領域的血清分離凝膠市場佔有率從2024 年到2032 年將出現顯著的複合年成長率。的分析方面發揮的關鍵作用。製藥公司需要高品質的凝膠萃取，以確保樣品的均質性和一致性。此外，對個人化醫療的日益關注和慢性病的興起進一步刺激了這種需求。因此，製造商正在增加產量以滿足製藥行業的需求，從而導致市場成長。
2024年至2032年，歐洲市場的血清分離凝膠市場將呈現合理的複合年成長率。此外，對可靠的血小板分離產品的需求推動了對新醫療技術的需求。此外，嚴格的法規正在刺激整個地區的市場需求。製造商正在擴大生產並集中生產以滿足不斷成長的需求，確保歐洲市場的持續成長。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 診斷測試需求不斷成長
- 血液採集技術不斷進步
- 慢性病盛行率上升
- 擴大採用現場護理測試
- 產業陷阱與挑戰
- 血清分離膠管成本高
- 遵守監管要求
- 成長動力
- 成長潛力分析
- 技術景觀
- 監管環境
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 競爭定位矩陣
- 戰略展望矩陣
第 5 章：市場估計與預測：按產品分類，2021 - 2032 年
- 主要趨勢
- 不含整合管的血清分離凝膠
- 帶有整合管的血清分離凝膠
第 6 章：市場估計與預測：按最終用途分類，2021 - 2032 年
- 主要趨勢
- 醫院
- 血庫
- 製藥公司
- 其他最終用戶
第 7 章：市場估計與預測：按地區分類，2021 - 2032 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
- 亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 8 章：公司簡介
- Becton, Dickinson and Company
- BIOSIGMA S.p.A.
- Bio-Rad Laboratories, Inc.
- Cardinal Health, Inc.
- Danaher Corporation
- FL MEDICAL s.r.l.
- Greiner AG
- InterVacTechnology
- Qiagen N.V.
- Sekisui Chemical CO., LTD.
Global Serum Separation Gel Market will observe a CAGR of 5.9% from 2024 to 2032, primarily driven by product expansion from leading companies. These expansions are a response to the growing need for efficient and reliable diagnostic tools in medical laboratories. Serum separation gel plays an important role in the precision and accuracy of blood separation, which is important for diagnostic tests. For example, in August 2023, Osoh Corporation announced the planned dissemination of TOYOPEARL-TSKgel PW operations at their separation refinery located in Shunan, Yamaguchi Prefecture. This decision is in response to the increasing demand for purification.
Companies are investing heavily in advanced manufacturing facilities and new technologies to improve efficiency and meet growing global demand. In addition, the growing prevalence of chronic diseases and the need for regular health check-ups further support the market demand. As a result, the serum isolation gel market is poised for strong growth, supported by leading-edge technological advances and strategic infrastructure.
The overall Serum Separation Gel industry size is classified based on product, end-use application, and region.
The integrated tubeless serum isolation gel segment will grow robustly from 2024 to 2032, driven by the need for simple, cost-effective solutions in clinical research environments. Furthermore, the increasing demand for analytical accuracy and modeling efficiency in diagnostics efforts contributes to this demand. Consequently, manufacturers are focused on increasing the quality and availability of serum separation gels without the use of integrated devices.
The serum separation gel market share from the pharmaceutical company segment will register a notable CAGR from 2024 to 2032. This growth is attributed to the key role this gel plays in blood purification and providing accurate and reliable analysis for essential drug development and clinical trials. Pharmaceutical companies require high-quality gel extraction to ensure sample homogeneity and consistency. In addition, the expanding focus on personalized medicine and the rise of chronic diseases further encourage this demand. Consequently, manufacturers are increasing production to meet the needs of the pharmaceutical industry, leading to market growth.
Serum isolation gel market from the European segment will exhibit a reasonable CAGR from 2024 to 2032. This is due to the rapidly improving healthcare infrastructure in the region, along with the increasing incidence of chronic diseases requiring daily monitoring. Moreover, the need for reliable platelet isolation products drives the demand for new medical technologies. Additionally, stringent regulations are fueling the market demand across the region. Manufacturers are expanding production and centralizing production to meet this growing demand, ensuring continued market growth in Europe.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising demand for diagnostic testing
- 3.2.1.2 Growing technological advancement in blood collection
- 3.2.1.3 Rising prevalence of chronic diseases
- 3.2.1.4 Growing adoption of point-of-care testing
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of serum separation gel tubes
- 3.2.2.2 Compliance with regulatory requirements
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technological landscape
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Serum separation gel without integrated tubes
- 5.3 Serum separation gel with integrated tubes
Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Hospitals
- 6.3 Blood banks
- 6.4 Pharmaceutical companies
- 6.5 Other end-users
Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Rest of Europe
- 7.4 Asia Pacific
- 7.4.1 Japan
- 7.4.2 China
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
- 7.4.6 Rest of Asia Pacific
- 7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
- 7.5.4 Rest of Latin America
- 7.6 Middle East and Africa
- 7.6.1 Saudi Arabia
- 7.6.2 South Africa
- 7.6.3 UAE
- 7.6.4 Rest of Middle East and Africa
Chapter 8 Company Profiles
- 8.1 Becton, Dickinson and Company
- 8.2 BIOSIGMA S.p.A.
- 8.3 Bio-Rad Laboratories, Inc.
- 8.4 Cardinal Health, Inc.
- 8.5 Danaher Corporation
- 8.6 FL MEDICAL s.r.l.
- 8.7 Greiner AG
- 8.8 InterVacTechnology
- 8.9 Qiagen N.V.
- 8.10 Sekisui Chemical CO., LTD.
